DR
DRMA.US Dermata Therapeutics Inc
- Market cap
- USD 3.06M
- P/E
- -
- P/B
- 0.93x
- ROE
- -260.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DRMA.US undervalued?
Graham numberThe Graham number of Dermata Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dermata Therapeutics Inc fundamental analysis
No fundamental analysis for Dermata Therapeutics Inc yet.
Dermata Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Full company profileDermata Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dermata Therapeutics Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.8K |
| Gross Profit | -1.36K | -322.00 | - | - | - | - | - | - |
| Operating Income | -4.47M | -3.17M | -7.86M | -9.67M | -8.04M | -12.5M | -7.77M | -10.4M |
| EBITDA | -4.47M | -3.04M | -7.84M | -9.67M | 247K | -12.3M | -7.77M | -10.3M |
| Net Income | -4.72M | -3.24M | -7.95M | -9.61M | -7.80M | -12.3M | -7.56M | -10.2M |
| EPS | -1,361 | -933 | -153 | -2,088 | -400 | -80 | -8.16 | -1.99 |
| Balance Sheet | ||||||||
| Total Assets | 2.07M | 605K | 11.6M | 6.94M | 7.98M | 3.53M | 7.86M | 6.64M |
| Total Liabilities | 2.28M | 3.78M | 1.52M | 923K | 1.62M | 1.97M | 1.64M | 2.73M |
| Shareholders' Equity | -210K | -3.18M | 10.1M | 6.02M | 6.36M | 1.56M | 6.22M | 3.91M |
| Cash & Short-term Investments | 1.99M | 530K | 10.8M | 6.24M | 7.44M | 3.16M | 7.52M | 4.82M |
| Total Debt | 1.28M | 3.55M | - | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.92M | -4.03M | -5.69M | -8.83M | -6.41M | -11.2M | -7.76M | -10.1M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 | 218K |
| Free Cash Flow | -3.92M | -4.03M | -5.69M | -8.83M | -6.41M | -11.2M | -7.76M | -10.3M |
| Ratios | ||||||||
| ROE | - | - | -78.6% | -159.6% | -122.7% | -787.1% | -121.5% | -260.7% |
| ROA | -228.5% | -534.6% | -68.4% | -138.4% | -97.7% | -347.7% | -96.1% | -153.4% |
| Net Profit Margin | - | - | - | - | - | - | - | -10,300.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dermata Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 2.29M | 44 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Aug 1, 2025.
Who owns Dermata Therapeutics Inc
- Insiders 22.50%
- Institutions 12.53%
- Public & others 64.97%
- Shares outstanding 4.93M
- Free float 3.29M
Top funds holding DRMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 19.0K | 0.38% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.11K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding DRMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 20.2K | 0.41% | -58.20% | Jun 2026 |
| Welch & Forbes LLC | 20.0K | 0.40% | 0.00% | Jun 2026 |
| State Street Corp | 18.7K | 0.38% | 0.00% | Jun 2026 |
| UBS Group AG | 16.8K | 0.34% | -52.83% | Jun 2026 |
| Susquehanna International Group, LLP | 16.0K | 0.32% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 14.8K | 0.30% | 0.00% | Jun 2026 |
| Advisory Alpha, LLC | 10.0K | 0.20% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.86K | 0.08% | +439.11% | Jun 2026 |
| Mcf Advisors, LLC | 1.73K | 0.04% | 0.00% | Jun 2026 |
| Barclays PLC | 270.00 | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 101.00 | 0.00% | 0.00% | Jun 2026 |
| HIGHLINE WEALTH PARTNERS LLC | 26.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Dermata Therapeutics Inc company profile
- Company name
- Dermata Therapeutics Inc
- Ticker
- DRMA.US
- Exchange
- USA Stocks
- Listed since
- Aug 13, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- 3525 Del Mar Heights Rd., San Diego, CA, United States, 92130
- Phone
- 858 800 2543
- Website
- dermatarx.com
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics Inc management
7- Mr. Gerald T. ProehlFounder, President, CEO & Chairman · born 1959
- Mr. David F. HaleCo-Founder & Lead Independent Director · born 1949
- Ms. Kyri K. Van Hoose CPA, M.B.A.Senior VP & CFO · born 1978
- Dr. Christopher J. Nardo M.P.H., Ph.D.Senior VP & Chief Development Officer · born 1965
- Mr. Sean ProehlAssociate General Counsel
- Ms. Kyra PeckaitisVice President of Marketing
- Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.Senior Vice President of Regulatory Affairs & Quality Assurance · born 1951